Synapse - Find an Expert

11740 Results

Massively parallel sequencing analysis of microsatellite instability in breast cancer

Meeting Abstract

Selenica, P.; Pareja, F.; Ferrando, L.; Brown, D. N.; Riaz, N.; Weigelt, B.; Drago, J. Z.; Robson, M. E.; Razavi, P.; Chandarlapaty, S.; more...
Cancer Research (2020)

Fulltext@MSK | Save

The genomic landscape of breast cancer in African American women

Meeting Abstract

Serna-Tamayo, C.; Drago, J. Z.; Dos Anjos, C.; Herbert, J.; Pareja, F.; Modi, S.; Jhaveri, K.; Dang, C.; Solit, D. B.; Norton, L.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)

Meeting Abstract

Schmid, P.; Cortes, J.; Robson, M.; Iwata, H.; Hegg, R.; Verma, S.; Nechaeva, M.; Xu, B.; Haddad, V.; Imedio, E. R.; more...
Cancer Research (2020)

Fulltext@MSK | Save

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Meeting Abstract

Robson, M.; Im, S. A.; Senkus, E.; Xu, B.; Domchek, S.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Armstrong, A.; more...
Cancer Research (2020)

Fulltext@MSK | Save

RAD51B loss-of-function variants confer susceptibility to hereditary breast and ovarian cancers and result in tumors with genomic features of homologous recombination repair defects

Meeting Abstract

Mandelker, D.; Mukherjee, S.; Setton, J.; Selenica, P.; Kemel, Y.; Ceyhan-Birsoy, O.; Sheehan, M.; Tkachuk, K.; Brown, D. N.; Powell, S.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Polygenic breast cancer risk modification in carriers of high and intermediate risk gene mutations

Meeting Abstract

Gallagher, S.; Hughes, E.; Wagner, S.; Tshiaba, P.; Rosenthal, E.; Roa, B. B.; Kurian, A.; Domchek, S.; Garber, J.; Lancaster, J. M.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Surgical decision making and clinical outcomes in breast cancer (BC) patients (pts) with germline alterations in moderate risk BC susceptibility genes (CHEK2, PALB2 and ATM)